Replies to post #428474 on Anavex Life Sciences Corp (AVXL)

[bas2020]

It's the factual data of the AD trial that conclude an astonishingly positive outcome, where patients have functionally IMPROVED!
It's rather dubious how FUDsters continue to neglect and discount the successful results... Don't you, Dr. FUD?

ANAVEX®2-73 (blarcamesine) Meets Co-Primary and Key Secondary Endpoints for Patients with Early Alzheimer’s Disease

• Odds Ratio of ADAS-Cog meaningful improvement in cognition at threshold of -0.5 points or less (90% CI) 1.839 (1.17, 2.94) P = 0.015

• Odds Ratio of ADCS-ADL meaningful improvement in function at threshold of +3.5 points or higher (90% CI) 2.67 (1.17, 6.13) P = 0.0255

• ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks
• Mean difference in ADAS-Cog score change of -1.85 points

• Compared to placebo, ANAVEX®2-73 (blarcamesine) reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by CDR-SB

It's estimated that the super responder group, identified by the Odds Ratios, is up to 30% of treated patients.